Immunome Statistics
Total Valuation
Immunome has a market cap or net worth of $2.85 billion. The enterprise value is $2.59 billion.
Important Dates
The last earnings date was Thursday, November 6, 2025, after market close.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Immunome has 110.33 million shares outstanding. The number of shares has increased by 47.92% in one year.
| Current Share Class | 110.33M |
| Shares Outstanding | 110.33M |
| Shares Change (YoY) | +47.92% |
| Shares Change (QoQ) | +1.09% |
| Owned by Insiders (%) | 1.23% |
| Owned by Institutions (%) | 79.50% |
| Float | 104.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 212.03 |
| Forward PS | n/a |
| PB Ratio | 8.99 |
| P/TBV Ratio | 10.82 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 267.14 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.90, with a Debt / Equity ratio of 0.02.
| Current Ratio | 8.90 |
| Quick Ratio | 8.67 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -93.04% and return on invested capital (ROIC) is -53.25%.
| Return on Equity (ROE) | -93.04% |
| Return on Assets (ROA) | -46.48% |
| Return on Invested Capital (ROIC) | -53.25% |
| Return on Capital Employed (ROCE) | -77.20% |
| Weighted Average Cost of Capital (WACC) | 16.47% |
| Revenue Per Employee | $57,613 |
| Profits Per Employee | -$1.33M |
| Employee Count | 168 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +153.38% in the last 52 weeks. The beta is 2.23, so Immunome's price volatility has been higher than the market average.
| Beta (5Y) | 2.23 |
| 52-Week Price Change | +153.38% |
| 50-Day Moving Average | 20.27 |
| 200-Day Moving Average | 12.83 |
| Relative Strength Index (RSI) | 71.14 |
| Average Volume (20 Days) | 2,104,977 |
Short Selling Information
The latest short interest is 17.53 million, so 15.89% of the outstanding shares have been sold short.
| Short Interest | 17.53M |
| Short Previous Month | 15.88M |
| Short % of Shares Out | 15.89% |
| Short % of Float | 16.82% |
| Short Ratio (days to cover) | 6.15 |
Income Statement
In the last 12 months, Immunome had revenue of $9.68 million and -$222.74 million in losses. Loss per share was -$2.81.
| Revenue | 9.68M |
| Gross Profit | -164.73M |
| Operating Income | -206.85M |
| Pretax Income | -222.74M |
| Net Income | -222.74M |
| EBITDA | -204.56M |
| EBIT | -206.85M |
| Loss Per Share | -$2.81 |
Full Income StatementBalance Sheet
The company has $272.64 million in cash and $4.01 million in debt, with a net cash position of $268.63 million or $2.43 per share.
| Cash & Cash Equivalents | 272.64M |
| Total Debt | 4.01M |
| Net Cash | 268.63M |
| Net Cash Per Share | $2.43 |
| Equity (Book Value) | 263.92M |
| Book Value Per Share | 2.88 |
| Working Capital | 248.48M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$185.03 million and capital expenditures -$6.81 million, giving a free cash flow of -$191.84 million.
| Operating Cash Flow | -185.03M |
| Capital Expenditures | -6.81M |
| Free Cash Flow | -191.84M |
| FCF Per Share | -$1.74 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -2,137.10% |
| Pretax Margin | -2,301.30% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Immunome does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -47.92% |
| Shareholder Yield | -47.92% |
| Earnings Yield | -7.80% |
| FCF Yield | -6.72% |
Analyst Forecast
The average price target for Immunome is $31.22, which is 20.68% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $31.22 |
| Price Target Difference | 20.68% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 98.36% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Immunome has an Altman Z-Score of 8.6 and a Piotroski F-Score of 2.
| Altman Z-Score | 8.6 |
| Piotroski F-Score | 2 |
